In this study, we conducted a PRM-MS analysis on 1085 FTC and FTA samples from 18 clinical centers, quantifying the expression levels of 94 differentially expressed proteins and employing machine learning to identify potential therapeutic targets for FTC. Subsequently, we conducted a series of biological experiments to validate the relevance and impact of the four of these proteins (MVP, IGF2R, HDAC1, and H1-5) on the initiation and progression of FTC.